Publication: TSUBAKI, a Study of Bardoxolone Methyl in Patients with Diabetic CKD

TSUBAKI was a Phase 2, randomized, multicenter, double-blind, placebo-controlled study of bardoxolone methyl in patients with type 2 diabetes and stage 3-4 chronic kidney disease. The primary efficacy endpoint was change from baseline in GFR measured by inulin clearance at week 16.